CAPR MEXC RealStocks
Own real CAPR shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-12 22:03:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Capricor Therapeutics Inc. (CAPR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $10.23, with a market capitalization of $515.69M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.96 to $40.37. This page covers its latest market performance, valuation, price trends and company information.
$515.69M | |
$10.95 | |
$11.21 | |
$9.89 | |
$11.22 | |
4.38M | |
6.00M | |
-- | |
$40.37 | |
$2.96 | |
-- | |
-- |
Capricor Therapeutics Inc. (CAPR) is trading at $10.25 in after-hours trading as of 2026-11-12 22:00:00, up 0.17% ($0.02) from the regular-session close of $10.23.
After-hours trading shows how investors are pricing CAPR after the regular session closes. The current after-hours price is near the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Capricor Therapeutics Inc. (CAPR) moved from $8.24 to $10.23, representing a gain of 24.20% ($1.99).
The stock traded between $7.15 and $11.23 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 5.67 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 19.4%
CAPR is currently trading at $10.23, placing it 19.4% of the way from its 52-week low of $2.96 to its 52-week high of $40.37. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 231 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Capricor Therapeutics Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Capricor Therapeutics Inc. (CAPR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CAPR, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CAPR shares and USD.
CAPR Shares to USD
1.00 CAPR shares = 10.234 USD
Calculations are estimates based on the latest available price and are for reference only.